All In Biotech

Drug Trial Radar · NCT05783323

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions (LANTERN)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

13

Planned (sponsor's estimate)

Start

Feb 14, 2024

Primary completion

Oct 1, 2028

Study completion Oct 1, 2030

Sponsor

Lead sponsor
Children's Hospital of PhiladelphiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bayer
First posted
Mar 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.

Conditions

  • Differentiated Thyroid Cancer
  • Pediatric Cancer
  • Cancer
  • Cancer, Thyroid

Interventions

  • Larotrectinib monotherapyDrug

    Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.

  • 131I therapyRadiation

    Patients will receive 131I therapy after 6 months of larotrectinib.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with complete pulmonary structural responseTime frame: 18 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.